Hydroxamates as TACE and MMP Inhibitors
Journal of Medicinal Chemistry, 2004, Vol. 47, No. 25 6269
(9) Woessner, J. F., Nagase, S., Eds. Marix Mealloproteinases and
TIMPS; Oxford University Press: New York, 2000.
(23) Weingarton, H.; Feder, J. Spectrophotometric assay for vert-
ibrate collagenase. Ana. Biochem. 1985, 147, 437. Inhibitor
concentrations were run in triplicate. MMPI IC50 values deter-
minations were calculated from a four-parameter logistic fit of
the data with in a single experiment. The final values given here
are the mean triplicate values of the sample.
(24) Jin, G.; Huang, X.; Black, R.; Wolfson, M.; Rauch, C.; McGregar,
H.; Ellestad, G. A.; Cowling, R. Continuous fluorimetric assay
for tumor necrosis factor-R converting enzyme. Anal. Biochem.
2002, 302, 269.
(25) (a) Yip, D.; Ahmad, A.; Karapetis, C. S.; Hawkins, C. A.; Harper,
P. G. Matrix metalloproteinase inhibitors: Applications in
oncology. Invest. New Drugs. 1999, 17, 387. (b) Nelson, A. R.;
Fingleton, B.; Rothenberg, M. L.; Matrisian, L. M. Matrix
metalloproteinases: Biological activity and clinical implications.
J. Clin. Oncol. 2000, 18, 1135.
(26) Levin, J. I.; Du, M. T.; Di Joseph, J. F.; Killar, L. M.; Sung, A.;
Walter, T.; Sharr, M. A.; Roth, C. E.; Moy, F. J.; Powers, R.;
Jin, G.; Cowling, R.; Skotnicki, J. S. The discovery of anthranilic
acid based MMP-Inhibitors. Part. 1: SAR of the 3-position.
Bioorg. Med. Chem. Lett. 2001, 11, 235.
(27) (a) Newton, R. C.; Decicco, C. P. Therapeutic potential and
strategies for inhibiting tumor necrosis factor-R. J. Med. Chem.
1999, 42, 2295. (b) Duan, J. J. W.; Chen, L.; Wasserman, Z. R.;
Lu, Z.; Liu, R. Q.; Covington, M. B.; Qian, M.; Hardman, K. D.;
Magolda, R. L.; Newton, R. C.; Christ, D. D.; Wexler, R. R.;
Decicco, C. P. Discovery of γ-lactam hydroxamic acids as selective
inhibitors of tumor necrosis factor R-converting enzyme: Design,
synthesis and structure-activity relationships. J. Med. Chem.
2002, 45, 4954. (c) Kottirsch, G.; Koch, G.; Feifel, R.; Neumann,
U. â-Aryl-succinic acid hydroxamates as dual inhibitors of matrix
metalloproteinases and TNF-R converting enzyme. J. Med.
Chem. 2002, 45, 2289. (d) Trifilieff, A.; Walker, C.; Keller, T.;
Neumann, U. Pharmacological profile of PKF242-484 and
PKF241-466, novel dual inhibitors of TNF-R converting enzyme
and matrix metalloproteinases in models of airway inflamma-
tion. Br. J. Pharmacol. 2002, 135, 1655. (e) Letavic, M. A.; Axt,
M. Z.; Barberia, J. T.; Carty, T. J.; Danley, D. E.; Geoghegan,
K. F.; Halim, N. S.; Hoth, L. R.; Kamath, A. V.; Laird, E. R.;
Lopresti-Morrow, L. L.; McClure, K. F.; Mitchell, P. G.; Natara-
jan, V.; Noe, M. C.; Pandit, J.; Reeves, L.; Schulte, G. K.; Snow,
S. L.; Sweeney, F. J.; Tan, D. H.; Yu, C. H. Synthesis and
biological activity of piperazine based dual MMP-13 and TNF-R
converting enzyme inhibition. Bioorg. Med. Chem. Lett. 2002,
12, 1387.
(28) (a) Gatanaga, T.; Hwang, C.; gatanaga, M.; Cappuccini, F.;
Yamamoto, R.; Granger, G. The Regulation of TNF mRNA
synthesis, membrane expressino and release by PMA-and LPS-
stimulated human monocytic THP-1 cells in vitro. Cellular
Immun. 1991, 138, 10. (b) Mohler, K. M.; Sleath, P. R.; Fitzner,
J. N.; Cerretti, D. P.; Alderson, M.; Kerwar, S. S.; Torrance, D.
S.; Otte-Evans, C.; Greenstreet, T.; Weerawarna, K.; Kronheim,
S. R.; Petersen, M.; Gerhart, M.; Kozlosky, C. J.; March, C. J.;
Black, R. A. +Protection against a lethal dose of endotoxin by
an inhibitor of tumor necrosis factor processing. Nature 1994,
370, 218. (c) Levin, J. I.; Venkatesan, A. M.; Cole, D. C.; Chen,
J. M.; Davis, J. M.; Grosu, G. T.; Alkynyl containing hydroxamic
acid compounds as matrix metalloproteinase and TACE inhibi-
tors. US Patent 6,340,691 B1, 2002.
(10) Clark, I. M.; Parker, A. E. Metalloproteinases: Their role in
arthritis and potential as therapeutic target. Exp. Opin. Ther.
Target 2003, 7, 19.
(11) Geroge, S. J. Therapeutic Potential of matrix metalloproteinase
inhibitors in atherosclerosis. Exp. Opin. Investig. Drugs 2000,
9, 993.
(12) Fingleton, B.; Matrisian, L. M. Matrix Metalloproteinases in
Cancer. In Matrix Metalloproteinases in Cancer Therapy; Clen-
deninn, N. J., Appelet, K., Eds.; Humana Press: Totowa, NJ,
2001; p 85.
(13) Baker, A. H.; Edwards, D. R.; Murphy, G. Metalloproteinase
Inhibitors: Biological actions on therapeutic opportunities. J.
Cell. Sci. 2002, 115, 3719.
(14) (a) Mitchell, P. G.; Magna, H. A.; Reeves, L. M.; Lopresti-Morrow,
L. L.; Yocum, S. A.; Rosner, P. J.; Geoghegan, K. F.; Hambor, J.
E. Cloning expression and type II collagenolytic activity of matrix
metalloproteinase-13 fron human osteoarthritic cartilage. J.
Clin. Invest. 1996, 97, 761. (b) Mousa, S. A. Mechanism of
angiogenesis in vascular disorders. Potential therapeutic targets.
Drugs Future 1998, 23, 51.
(15) Ray, J. M.; Stetler-Stevenson, W. G. The role of matrix metal-
loproteinases and their inhibitors in tumor invasion, metastasis
and angiogenesis. Eur. Respir. J. 1994, 7, 2062.
(16) George, S. J. Tissue Inhibitors of matrix metalloproteinases in
artherosclerosis. Curr. Opin. Lipidol. 1998, 9, 413.
(17) Venkatesan, A. M.; Grosu, G. T.; Davis, J. M.; Baihua, H.;
Ellingboe, J.; Baker, J. L.; Skotnicki, J. S.; Arie, Z.; DiJoseph,
J. F.; Sung, A.; Michele, A. S.; Killar, L. M.; Thomas, W.;
Guixian, J.; Cowling, R. Synthesis and structure-activity
relationship of R-sulfonylhydroxamic acids as novel, orally active
matrix metalloproteinase inhibitors for the treatment of osteoar-
thritis. J. Med. Chem. 2002, 46, 2361.
(18) Venkatesan, A. M.; Davis, J. M.; Grosu, G. T.; Baker, J. L.;
Ellingboe, J.; Arie, Z.; Levin, J. I.; Sandanayaka, V. P.; Milla,
D.; Skotnicki, J. S.; DiJoseph, J. F.; Sung, A.; Michele, A. S.;
Killar, L. M.; Thomas, W.; Guixian, J.; Cowling, R.; Tillett, J.;
Weiguang, Z.; McDevitt, J.; Zhang, B. X. Synthesis and structure-
activity relationship of N-substituted 4-arylsulfonylpiperidine-
4-hydroxamic acids as novel, orally active matrix metallopro-
teinase inhibitors for the treatment of osteoarthritis. J. Med.
Chem. 2002, 46, 2376.
(19) (a) Renkiewicz, R.; Qiu, L.; Lesch, C.; un, X.; Devalaraja, R.;
Cody, T.; Kaldjian, E.; Welgus, H.; Baragi, V. Broad spectrum
matrix metalloproteinase inhibitor marimastat induced muscu-
loskeletal side effects in rats. Arthritis Rheum. 2003, 48, 1742.
(b) Levin, J. I.; Chen, J. M.; Cheung, K.; Cole, D.; Crago, C.;
Delos Santos, E.; Du, X.; Khafizova, G.; MacEwan, G.; Niu, C.;
Salaski, E. J.; Zask, A.; Cummons, T.; Sung, A.; Xu, J.; Zhang,
Y.; Xu, W.; Ayral-Kaloustian, S.; Jin, G.; Cowling, R.; Barone,
D.; Mohler, K. M.; Black, R. A.; Skotnicki, J. S. Acetylenic TACE
Inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.
Bioorg. Med. Chem. Lett. 2003, 2799.
(20) Maskos, K.; Fernandez-Catalan, C.; Huber, R.; Bourenkov, G.
P.; Bartunik, H.; Ellestad, G. A.; Reddy, P.; Wolfson, M. F.;
Rauch, C. T.; Castner, B. J.; Davis, R.; Clarke, H. R. G.; Petersen,
M.; Fitzner, J. N.; Cervetti, D. P.; March, C. J.; Paxton, R. J.;
Block, R. P.; Bode, W. Crystal structure of the catalytic domain
of human tumor necrosis factor-R-converting enzyme. Proc. Natl.
Acad. Sci. U.S.A. 1998, 95, 3408.
(21) The relative stereochemistry between sulfur-oxygen bond and
the adjacent carbon bearing the hexyl side chain was determined
by a single-crystal X-ray crystallography. It was found that the
faster moving isomer was (2R)-N-hydroxy-2-[(S)-4-methoxyphen-
yl)sulfinyl]octanamide (one distereomer, but the absolute ster-
eochemistry at sulfur and carbon is unknown). The slower
moving isomer was (2S)-N-hydroxy-2-[(S)-4-methoxyphenyl)-
sulfinyl]octanamide (one distereomer, but the absolute stereo-
chemistry at sulfur and carbon is unknown). For the rest of the
sulfoxide derivatives reported in this paper, for the faster moving
isomer the relative stereochemistry between the SdO bond and
adjacent substituent is tentatively designated as SR or RS and
the slow moving isomer is tentatively designated as SS or RR.
The absolute stereochemistry unknown. Compounds were sepa-
rated by SiO2 column chromatography (silica gel 60, particle size
0.040-0.063 mm, 230-400 mesh, Merck KgaA, Germany) (TLC
plates used were Uniplate, Silica Gel-GF, 250 µm).
(29) McMartin, C.; Bohacek, R. S. QXP: Powerful, rapid computer
algorithms for structure-based drug design. J. Comput.-Aided
Mol. Design 1997, 11, 333.
(30) Zhang, Y.; Xu, J.; Levin, J.; Hegen, M.; Li, G.; Robertshaw, H.;
Brennan, F.; Cummons, T.; Clarke, D.; Vansell, N.; Nickerson-
Nutter, C.; Barone, D.; Mohler, K.; Black, R.; Skotnicki, J.;
Gibbons, J.; Feldmann, M.; Frost, P.; Larsen, G.; Lin, L.-L.
Identification and characterization of 4-{[4-(2-butynyloxy)phen-
yl]sulfonyl}-N-hydroxy-2,2-dimethyl-(3S)-thio morpholinecar-
boxamide (TMI-1),
a novel dual tumor necrosis factor-R-
converting enzyme/matrix metalloprotease inhibitor for the
treatment of rheumatoid arthritis. J. Pharmacol. Exp. Ther.
2004, 309, 348.
(31) Ichihara, J.; Matsuo, T.; Hanafusa, T.; Ando, T. The combination
of potassium fluoride and calcium fluoride: A useful heteroge-
neous fluorinating reagent. J. Chem. Soc., Chem. Commun.
1986, 793.
(22) Ashwood, M. S.; Gibson, A. W.; Houghton, D. G.; Humphrey, G.
R.; Roberts, D. C.; Wright, S. H. B. J. Chem. Soc., Perkin Trans.
1995, 6, 641.
JM040086X